MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $500,000, $1.50, $1,800, $3,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
MANGOCEUTICALS, INC. (MANG) filed an 8-K on Jan 27, 2025, reporting a material definitive agreement and unregistered equity sales.
AI Summary
On January 27, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Texas and its principal executive offices are located in Dallas.
Why It Matters
This 8-K filing signals significant corporate activity for MANGOCEUTICALS, INC., potentially impacting its stock price and investor outlook due to the material definitive agreement and equity sales.
Risk Assessment
Risk Level: medium — The filing involves a material definitive agreement and unregistered sales of equity, which can introduce uncertainty and potential dilution.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- January 27, 2025 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — City of Principal Executive Offices
- 15110 N. Dallas Parkway, Suite 600 (address) — Principal Executive Offices Address
FAQ
What is the nature of the material definitive agreement filed by MANGOCEUTICALS, INC.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
What type of equity securities were sold unregistered by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not elaborated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 27, 2025.
Where are MANGOCEUTICALS, INC.'s principal executive offices located?
MANGOCEUTICALS, INC.'s principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
What is the SEC file number for MANGOCEUTICALS, INC.?
The SEC file number for MANGOCEUTICALS, INC. is 001-41615.
Filing Stats: 1,831 words · 7 min read · ~6 pages · Grade level 11.9 · Accepted 2025-01-31 17:25:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $500,000 — MAAB had previously purchased rights to $500,000 owed by the Company to Barstool Sports,
- $1.50 — s common stock at a conversion price of $1.50 per share (the " Debt Conversion Shares
- $1,800 — al professionals at the rate of between $1,800 to $3,500 on a full-time basis per virt
- $3,500 — ionals at the rate of between $1,800 to $3,500 on a full-time basis per virtual profes
- $516,250 — . and Barstool Sports, Inc. relating to $516,250 of outstanding debt 10.2* January 1
Filing Documents
- form8-k.htm (8-K) — 63KB
- ex10-1.htm (EX-10.1) — 31KB
- ex10-2.htm (EX-10.2) — 47KB
- ex10-3.htm (EX-10.3) — 47KB
- ex10-4.htm (EX-10.4) — 59KB
- ex10-5.htm (EX-10.5) — 56KB
- ex10-6.htm (EX-10.6) — 43KB
- ex10-7.htm (EX-10.7) — 115KB
- ex10-1_001.jpg (GRAPHIC) — 13KB
- ex10-1_002.jpg (GRAPHIC) — 134KB
- 0001493152-25-004501.txt ( ) — 914KB
- mgrx-20250127.xsd (EX-101.SCH) — 3KB
- mgrx-20250127_lab.xml (EX-101.LAB) — 33KB
- mgrx-20250127_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: January 31, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer